Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

BioSig Technologies Partners Mayo Clinic to Treat Arrhythmia

BioSig Technologies (BSGM) signs agreement with Mayo Foundation for improving arrhythmia treatment along with covering therapies for autonomic nervous system disease.

Here's Why You Should Invest in ResMed (RMD) Stock Right Now

Investors continue to be optimistic about ResMed (RMD) on its stellar performance.

Cooper Companies (COO) to Post Q4 Earnings: What's in Store?

Better-than-expected performance at CVI and CSI, and higher revenues are likely to have aided Cooper Companies (COO) in Q4 earnings.

Intuitive (ISRG) at a 52-Week High: What's Driving the Stock?

Intuitive Surgical (ISRG) has been gaining from a series of positive developments of late.

Mark Vickery headshot

Top Stock Reports for Walmart, Nike & Citigroup

Today's Research Daily features new research reports on 16 major stocks, including Walmart Inc. (WMT), Nike, Inc. (NKE) and Citigroup Inc. (C).

Medtronic Displays All-Business-Line Growth Despite Cost Woes

Medtronic's (MDT) Diabetes group is expanding internationally on the strong rollout of its MiniMed 670G in untapped markets.

Hologic's LOCalizer RFID Tag in Breast Health Gets CE Mark

Hologic (HOLX) wins the CE Mark for long-term use of LOCalizer RFID tag, providing more flexibility to breast-conserving surgery.

QIAGEN and DiaSorin Get FDA Approval for LIAISON QFT-Plus

QIAGEN (QGEN) and DiaSorin begin the commercial launch of the QFT-Plus test in the United States, following the FDA clearance.

Neogen's (NEOG) Food Safety Test Receives AOAC Clearance

Neogen's (NEOG) Reveal 3-D safety test for checking peanut contamination in food items gets approval from the AOAC.

Bio-Rad's Blood Typing Market Growth Strong on New Products

Bio-Rad's (BIO) new product acceptance in the United States is a positive with the recent 510(k) clearance of the IH-Reader 24.

Amedisys (AMED) to Broaden Hospice Base With Asana Purchase

Asana's acquisition to be the third hospice care buyout of Amedisys (AMED) in 2019.

Medtronic Gets FDA Nod for IN.PACT AV for ESRD Patients

Medtronic (MDT) receives FDA clearance for IN.PACT AV for the treatment of arteriovenous failures in patients undergoing hemodialysis.

Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

Investor confidence in Tandem Diabetes (TNDM) stock is at a high, thanks to solid prospects.

Here's Why You Should Buy Thermo Fisher (TMO) Stock Now

Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar performance.

NuVasive Gets FDA Nod for CoRoent Small Interlock System

NuVasive (NUVA) receives the FDA clearance for expanded use of its Interlock system for minimally disruptive spine surgery at multiple levels.

Omnicell (OMCL) Rides on Global Expansion, Strategic R&Ds

Omnicell's (OMCL) diligent focus on product innovation through R&D is encouraging.

Henry Schein to Showcase New Dental Offerings at GNYDM

Henry Schein's (HSIC) suite of solutions, education, & social media activity featuring dental industry leaders to enable dental professionals to explore new options revolutionizing digital dentistry.

Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan

The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.

Dexcom (DXCM) Hits a 52-Week High: What's Driving the Stock?

Dexcom (DXCM) gains from several positive developments.

Myriad Genetics' Test Added in Disease Activity Measure List

Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.

Hologic (HOLX) Set to Divest Medical Aesthetics Business

Hologic (HOLX) to sell off its medical aesthetics business to focus on other core segments.

Zacks.com featured highlights include: Nexstar Broadcasting Group, ResMed, Lam Research, Qorvo and Northrop Grumman

Zacks.com featured highlights include: Nexstar Broadcasting Group, ResMed, Lam Research, Qorvo and Northrop Grumman

NUVA or RMD: Which Is the Better Value Stock Right Now?

NUVA vs. RMD: Which Stock Is the Better Value Option?

What's in the Cards for Veeva Systems (VEEV) in Q3 Earnings?

Robust product portfolio and higher revenues are likely to have benefited Veeva Systems (VEEV) in third-quarter fiscal 2020 earnings.

Haemonetics Launches TEG 6s PlateletMapping Assay Cartridge

The global commercial availability of the cartridge is likely to bolster Haemonetics' (HAE) TEG portfolio.